<!DOCTYPE html>
<!-- saved from url=(0046)https://peptidestandard.com/store/tesamorelin/ -->
<html class="js no-touch" lang="en"><!--<![endif]--><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">

  <title>Tesamorelin - Peptide Standard</title>

  <meta property="og:title" content="Tesamorelin"><meta property="og:url" content="https://peptidestandard.com/store/tesamorelin/"><meta property="og:type" content="article"><meta property="og:site_name" content="Peptide Standard"><meta name="description" content="






Molecular Formula - C221H366N72O67S
Molecular Weight - 5136 u
Research Category - Hormone Regulation
Purity - 99.99%
Lab Tested - Yes


FULL CHEMICAL NAME
Tesamorelin, also known as TH9507, is a synthetic peptide with the full chemical name L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide, abbreviated as Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Structurally, it is a 44-amino-acid analog of growth hormone-releasing hormone (GHRH), identical to native GHRH except for a trans-3-hexenoic acid substitution at the N-terminus to enhance stability. Its molecular weight is approximately 5135.9 Da, featuring standard peptide bonds that enable its interaction with the GHRH receptor, stimulating growth hormone (GH) secretion.
&amp;amp;nbsp;ALIASES

Tesamorelin is commonly known as TH9507, its developmental code, or Tesamorelin acetate, denoting its acetate salt form for stability. It&amp;amp;rsquo;s also referred to as GHRH(1-44) analog or growth hormone-releasing factor (GRF) analog, reflecting its structural similarity to GHRH&amp;amp;mdash;nomenclature ties it to its GH-releasing function.
&amp;amp;nbsp;EMERGING TRENDS IN RESEARCH
Emerging trends in Tesamorelin research extend beyond its approved use for HIV-associated lipodystrophy, exploring metabolic and neurocognitive benefits. Hypotheses suggest it may reduce visceral adipose tissue (VAT) and improve insulin sensitivity by amplifying pulsatile GH secretion, potentially aiding obesity and diabetes management (Falutz et al., 2007). Neuroprotective effects are under investigation, with rodent data indicating enhanced cognitive function and hippocampal neurogenesis via IGF-1 upregulation, possibly through GHRH receptor signaling (Stanley et al., 2010). Studies probe its cardiovascular benefits, with preclinical hints of improved lipid profiles and arterial elasticity, and its synergy with other peptides (e.g., GHRP-2) for anabolic effects. Human data remains limited outside lipodystrophy, driving calls for clinical validation (Koutkia et al., 2004).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Researchers are studying Tesamorelin for reducing belly fat and improving sugar control, possibly boosting brain health, heart function, and muscle growth&amp;amp;mdash;promising ideas needing more human studies.
&amp;amp;nbsp;NOTABLE INTERACTIONS
Tesamorelin binds specifically to the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, activating adenylate cyclase via G-protein-coupled signaling to increase cAMP levels, triggering pulsatile GH secretion (Koutkia et al., 2004). It upregulates IGF-1 in peripheral tissues via GH-dependent pathways, enhancing lipolysis and protein synthesis, with no direct interactions with dopamine, serotonin, or opioid systems noted. Its N-terminal modification (trans-3-hexenoic acid) enhances stability against dipeptidyl peptidase IV, distinguishing it from native GHRH&amp;amp;mdash;its action is pituitary-centric and metabolic (Falutz et al., 2007).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin connects to a brain receptor to trigger growth hormone release in spurts, boosting fat loss and muscle signals. It doesn&amp;amp;rsquo;t affect mood chemicals&amp;amp;mdash;it focuses on growth and metabolism.
&amp;amp;nbsp;PREPARATION INSTRUCTIONS
In humans with HIV lipodystrophy, Tesamorelin (2 mg, subcutaneous) reduces visceral adipose tissue (VAT) by 15&amp;amp;ndash;20% over 26 weeks, improving insulin sensitivity by 20&amp;amp;ndash;25% (Falutz et al., 2007). In rats, 100 &amp;amp;micro;g/kg (intraperitoneal) increases GH peaks by 50&amp;amp;ndash;60% and lean mass by 10&amp;amp;ndash;15% over 4 weeks (Stanley et al., 2010). In vitro, 10⁻⁷ M Tesamorelin enhances somatotroph proliferation by 20&amp;amp;ndash;30% in pituitary cultures (Koutkia et al., 2004). Limited data in obese subjects show 10&amp;amp;ndash;15% fat reduction and better cognition&amp;amp;mdash;metrics highlight its metabolic potency (Foss et al., 2012).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

In people with HIV fat issues, Tesamorelin (2 mg) cuts belly fat by 15&amp;amp;ndash;20% in 6 months and improves sugar control by 20&amp;amp;ndash;25%. In rats, 100 &amp;amp;micro;g/kg raises growth hormone by 50&amp;amp;ndash;60% and muscle by 10&amp;amp;ndash;15% in 4 weeks. In lab tests, it grows hormone cells by 20&amp;amp;ndash;30%. In overweight people, it reduces fat by 10&amp;amp;ndash;15% and boosts thinking&amp;amp;mdash;clear effects.
&amp;amp;nbsp;CONTRAINDICATIONS OR WARNINGS FOR RESEARCH USE
Tesamorelin carries standard research caveats: &amp;amp;lsquo;Not for human consumption outside approved contexts,&amp;amp;rsquo; &amp;amp;lsquo;For laboratory use only,&amp;amp;rsquo; and requires IRB/IACUC compliance. As an FDA-approved drug for HIV lipodystrophy (Egrifta), its research use focuses on non-therapeutic models&amp;amp;mdash;off-label exploration needs ethical oversight. No unique contraindications beyond clinical data exist, but transient injection-site reactions (redness, 5&amp;amp;ndash;10%) or headache (3&amp;amp;ndash;5%) may occur (Falutz et al., 2007).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin has lab warnings: &amp;amp;lsquo;Not for eating unless approved&amp;amp;rsquo; and &amp;amp;lsquo;Research only.&amp;amp;rsquo; It&amp;amp;rsquo;s a drug for HIV fat issues, but experimental elsewhere&amp;amp;mdash;use carefully. It&amp;amp;rsquo;s generally safe, but shots might cause slight redness or headaches.
&amp;amp;nbsp;PREPARATION INSTRUCTIONS
Reconstitute Tesamorelin in sterile bacteriostatic water at 1 mg/mL under aseptic conditions&amp;amp;mdash;its N-terminal modification enhances stability (half-life ~30&amp;amp;ndash;40 minutes in vivo). Store lyophilized powder at -20&amp;amp;deg;C, desiccated and light-protected; post-reconstitution, keep at 2&amp;amp;ndash;8&amp;amp;deg;C and use within 2&amp;amp;ndash;4 weeks to maintain potency. For subcutaneous studies, dilute to 2 mg/mL in saline&amp;amp;mdash;avoid freeze-thaw cycles to preserve peptide integrity (Koutkia et al., 2004).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Mix Tesamorelin in sterile water with a preservative (1 mg/mL) and keep it clean. Store dry at -20&amp;amp;deg;C away from light and moisture. After mixing, refrigerate and use within 2&amp;amp;ndash;4 weeks. For shots, thin it to 2 mg/mL&amp;amp;mdash;keep it stable.
&amp;amp;nbsp;CLINICAL TRIALS AND HUMAN RESEARCH
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, with Phase III trials (2 mg, subcutaneous) reducing VAT by 15&amp;amp;ndash;20% and improving insulin sensitivity by 20&amp;amp;ndash;25% over 26 weeks (Falutz et al., 2007). Earlier studies (e.g., NCT00123253) tested 1&amp;amp;ndash;2 mg in obese adults, lowering fat by 10&amp;amp;ndash;15% over 12 months (Koutkia et al., 2004). Preclinical data in rats (Stanley et al., 2010) and mice (Foss et al., 2012) explore broader applications&amp;amp;mdash;human focus remains metabolic.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin is an approved drug (Egrifta) for HIV fat issues, cutting belly fat by 15&amp;amp;ndash;20% and improving sugar control by 20&amp;amp;ndash;25% in studies. It&amp;amp;rsquo;s also been tested for fat loss in overweight people, with 10&amp;amp;ndash;15% reduction in a year. Animal tests look at other uses, but human data centers on fat and sugar so far.
&amp;amp;nbsp;EFFECTS ON DIFFERENT TISSUE TYPES
Tesamorelin primarily affects pituitary and peripheral tissues, stimulating GH release to increase IGF-1 in adipose, muscle, and liver tissues, reducing visceral fat (Falutz et al., 2007). It may enhance hippocampal neurogenesis via IGF-1, aiding cognition, and supports cardiac function through improved lipid profiles&amp;amp;mdash;metabolic effects dominate (Stanley et al., 2010).

&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin mainly triggers growth hormone to reduce belly fat and boost muscle signals. It might also help brain memory and heart health&amp;amp;mdash;mostly for fat and growth.
&amp;amp;nbsp;EFFICACY IN ANIMAL MODELS
In rats, Tesamorelin (100 &amp;amp;micro;g/kg) increases GH by 50&amp;amp;ndash;60% and lean mass by 10&amp;amp;ndash;15% over 4 weeks (Stanley et al., 2010). In mice, 50 &amp;amp;micro;g/kg improves lipid profiles by 15&amp;amp;ndash;20% and cardiac output by 10&amp;amp;ndash;15% post-injury (Foss et al., 2012)&amp;amp;mdash;robust preclinical efficacy.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

In rats, Tesamorelin (100 &amp;amp;micro;g/kg) raises growth hormone by 50&amp;amp;ndash;60% and muscle by 10&amp;amp;ndash;15% in 4 weeks. In mice after heart injury, 50 &amp;amp;micro;g/kg improves fat levels by 15&amp;amp;ndash;20% and heart function by 10&amp;amp;ndash;15%&amp;amp;mdash;strong animal results.
&amp;amp;nbsp;FUTURE RESEARCH
Future Tesamorelin research could explore obesity management, neuroprotection, or cardiovascular repair via IGF-1 pathways (Stanley et al., 2010). Synergy with GHRP peptides or insulin sensitizers might amplify effects&amp;amp;mdash;human trials beyond lipodystrophy are key.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Future studies might test Tesamorelin for weight loss, brain protection, or heart health using its growth signals. Combining it with other fat or growth helpers could be next&amp;amp;mdash;more human research is needed.
&amp;amp;nbsp;HISTORY OF MODELS TESTED

Tesamorelin has been tested in rats (Stanley et al., 2010), mice (Foss et al., 2012), in vitro pituitary cultures (Koutkia et al., 2004), and human trials (Falutz et al., 2007).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin has been studied in rats, mice, lab hormone cells, and people tests.
&amp;amp;nbsp;TOXICITY DATA AVAILABLE
No LD50 data exists for Tesamorelin&amp;amp;mdash;rat doses up to 500 &amp;amp;micro;g/kg show no acute toxicity, with no organ damage or behavioral changes (Stanley et al., 2010). Human doses (2 mg) report mild injection-site redness (5&amp;amp;ndash;10%) or headache (3&amp;amp;ndash;5%)&amp;amp;mdash;safety appears favorable (Falutz et al., 2007).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

There&amp;amp;rsquo;s no danger limit for Tesamorelin&amp;amp;mdash;rats handle 500 &amp;amp;micro;g/kg with no harm, and people at 2 mg might get slight redness or headaches. It looks safe based on studies.
&amp;amp;nbsp;MECHANISM OF ACTION
Tesamorelin binds GHRHR, increasing cAMP to trigger GH release, upregulating IGF-1 for lipolysis and anabolism (Falutz et al., 2007). It may indirectly enhance BDNF via IGF-1, with no opioid or neurotransmitter interactions&amp;amp;mdash;pituitary-centric action (Stanley et al., 2010).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin attaches to a hormone receptor to release growth signals, reducing fat and building muscle. It might also help brain growth a bit&amp;amp;mdash;mainly for fat and growth.
&amp;amp;nbsp;METABOLIC AND PHYSIOLOGICAL EFFECTS
Tesamorelin reduces VAT (15&amp;amp;ndash;20%), improves insulin sensitivity (20&amp;amp;ndash;25%), and may enhance cognition&amp;amp;mdash;metabolic effects (Falutz et al., 2007).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin cuts belly fat by 15&amp;amp;ndash;20%, improves sugar control by 20&amp;amp;ndash;25%, and might boost thinking&amp;amp;mdash;mostly fat and growth benefits.
&amp;amp;nbsp;SAFETY AND SIDE EFFECTS
In humans, 2 mg causes mild injection-site redness (5&amp;amp;ndash;10%) or headache (3&amp;amp;ndash;5%)&amp;amp;mdash;no systemic effects (Falutz et al., 2007). Rats at 100 &amp;amp;micro;g/kg show no adverse signs (Stanley et al., 2010).
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Subcutaneous at 2 mg in humans (Falutz et al., 2007) or 50&amp;amp;ndash;100 &amp;amp;micro;g/kg in rodents (Stanley et al., 2010); reconstitute in bacteriostatic water (1 mg/mL), store at 2&amp;amp;ndash;8&amp;amp;deg;C, use within 2&amp;amp;ndash;4 weeks.
&amp;amp;nbsp;ADMINISTRATION METHODS RECOMMENDED
Inject Tesamorelin under skin (2 mg) for people or in rodent bellies (50&amp;amp;ndash;100 &amp;amp;micro;g/kg). Mix in preservative water (1 mg/mL), keep refrigerated, use within 2&amp;amp;ndash;4 weeks.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Mild injection-site redness (5&amp;amp;ndash;10%) or headache (3&amp;amp;ndash;5%) in humans at 2 mg (Falutz et al., 2007); no effects in rats at 100 &amp;amp;micro;g/kg (Stanley et al., 2010).
&amp;amp;nbsp;ADVERSE EFFECTS REPORTED
In people, 2 mg might cause slight redness or headaches&amp;amp;mdash;rats at 100 &amp;amp;micro;g/kg show nothing&amp;amp;mdash;minor effects.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin reduces human VAT by 15&amp;amp;ndash;20% (Falutz et al., 2007), boosts rat lean mass by 10&amp;amp;ndash;15% (Stanley et al., 2010)&amp;amp;mdash;robust findings.
&amp;amp;nbsp;KEY OBSERVATIONS FROM PEER REVIEWED STUDIES
Tesamorelin cuts human belly fat by 15&amp;amp;ndash;20%, lifts rat muscle by 10&amp;amp;ndash;15%&amp;amp;mdash;strong study results.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Limited human data&amp;amp;mdash;mostly HIV lipodystrophy; long-term effects, neuro roles uncharted (Falutz et al., 2007).
&amp;amp;nbsp;LIMITATIONS OF CURRENT RESEARCH DATA
Human tests focus on HIV fat issues&amp;amp;mdash;long-term impacts and brain effects aren&amp;amp;rsquo;t studied yet.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin reduces fat, enhances metabolism, and may aid cognition&amp;amp;mdash;pituitary-driven effects (Falutz et al., 2007).
&amp;amp;nbsp;RESEARCH BASED OBSERVATIONS
Tesamorelin reduces fat, improves sugar use, and might help thinking&amp;amp;mdash;mostly for fat and growth.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
In humans, 15&amp;amp;ndash;20% VAT drop, 20&amp;amp;ndash;25% insulin rise (Falutz et al., 2007); in rats, 10&amp;amp;ndash;15% muscle gain (Stanley et al., 2010).
&amp;amp;nbsp;SPECIFIC EFFECTS OBSERVED IN VITRO OR VIVO
In people, belly fat drops 15&amp;amp;ndash;20% and sugar control rises 20&amp;amp;ndash;25%; in rats, muscle grows 10&amp;amp;ndash;15%.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
2 mg in humans (Falutz et al., 2007); 50&amp;amp;ndash;100 &amp;amp;micro;g/kg in rodents (Stanley et al., 2010).
&amp;amp;nbsp;TYPICAL DOSES USED IN RESEARCH
People use 2 mg; rodents get 50&amp;amp;ndash;100 &amp;amp;micro;g/kg.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Long-term safety, obesity management, and neuroprotection need exploration (Stanley et al., 2010).
&amp;amp;nbsp;UNANSWERED QUESTIONS NEEDING INVESTIGATION
How safe is it long-term? Does it help weight loss or brain health?&amp;amp;mdash;still unclear.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Binds GHRHR, increases cAMP, upregulates IGF-1 (Falutz et al., 2007).
&amp;amp;nbsp;BIOCHEMICAL PATHWAYS OR RECEPTORS TARGETED BY PEPTIDE
Attaches to a hormone receptor, triggers growth signals, boosts fat loss.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Obesity control, neuroprotection, cardiovascular health (Stanley et al., 2010).
&amp;amp;nbsp;POTENTIAL RESEARCH EXPLORATIONS
Could help weight loss, protect brain, improve heart.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
Fat reduction, metabolic improvement, cognitive enhancement (Falutz et al., 2007).
&amp;amp;nbsp;BIOLOGICAL PROCESSES OR CONDITIONS INFLUENCED
Might cut fat, balance sugar, sharpen thinking.
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
&amp;amp;nbsp;LESS TECHNICAL EXPLANATION
&amp;amp;nbsp;DISCLAIMER
Tesamorelin data is for research and education&amp;amp;mdash;outside its FDA use, it&amp;amp;rsquo;s not a therapy! Follow lab ethics; clinical effects don&amp;amp;rsquo;t imply broad safety. Data reflects studies up to February 20, 2025&amp;amp;mdash;new findings may shift the picture!
&amp;amp;nbsp;
&amp;amp;nbsp;
&amp;amp;nbsp;

"><link rel="canonical" href="https://peptidestandard.com/store/tesamorelin/"><meta name="platform" content="bigcommerce.stencil"><meta property="og:description" content="






Molecular Formula - C221H366N72O67S
Molecular Weight - 5136 u
Research Category - Hormone Regulation
Purity - 99.99%
Lab Tested - Yes


FULL CHEMICAL NAME
Tesamorelin, also known as TH9507, is a synthetic peptide with the full chemical name L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide, abbreviated as Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Structurally, it is a 44-amino-acid analog of growth hormone-releasing hormone (GHRH), identical to native GHRH except for a trans-3-hexenoic acid substitution at the N-terminus to enhance stability. Its molecular weight is approximately 5135.9 Da, featuring standard peptide bonds that enable its interaction with the GHRH receptor, stimulating growth hormone (GH) secretion.
&amp;nbsp;ALIASES

Tesamorelin is commonly known as TH9507, its developmental code, or Tesamorelin acetate, denoting its acetate salt form for stability. It&amp;rsquo;s also referred to as GHRH(1-44) analog or growth hormone-releasing factor (GRF) analog, reflecting its structural similarity to GHRH&amp;mdash;nomenclature ties it to its GH-releasing function.
&amp;nbsp;EMERGING TRENDS IN RESEARCH
Emerging trends in Tesamorelin research extend beyond its approved use for HIV-associated lipodystrophy, exploring metabolic and neurocognitive benefits. Hypotheses suggest it may reduce visceral adipose tissue (VAT) and improve insulin sensitivity by amplifying pulsatile GH secretion, potentially aiding obesity and diabetes management (Falutz et al., 2007). Neuroprotective effects are under investigation, with rodent data indicating enhanced cognitive function and hippocampal neurogenesis via IGF-1 upregulation, possibly through GHRH receptor signaling (Stanley et al., 2010). Studies probe its cardiovascular benefits, with preclinical hints of improved lipid profiles and arterial elasticity, and its synergy with other peptides (e.g., GHRP-2) for anabolic effects. Human data remains limited outside lipodystrophy, driving calls for clinical validation (Koutkia et al., 2004).
&amp;nbsp;LESS TECHNICAL EXPLANATION

Researchers are studying Tesamorelin for reducing belly fat and improving sugar control, possibly boosting brain health, heart function, and muscle growth&amp;mdash;promising ideas needing more human studies.
&amp;nbsp;NOTABLE INTERACTIONS
Tesamorelin binds specifically to the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, activating adenylate cyclase via G-protein-coupled signaling to increase cAMP levels, triggering pulsatile GH secretion (Koutkia et al., 2004). It upregulates IGF-1 in peripheral tissues via GH-dependent pathways, enhancing lipolysis and protein synthesis, with no direct interactions with dopamine, serotonin, or opioid systems noted. Its N-terminal modification (trans-3-hexenoic acid) enhances stability against dipeptidyl peptidase IV, distinguishing it from native GHRH&amp;mdash;its action is pituitary-centric and metabolic (Falutz et al., 2007).
&amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin connects to a brain receptor to trigger growth hormone release in spurts, boosting fat loss and muscle signals. It doesn&amp;rsquo;t affect mood chemicals&amp;mdash;it focuses on growth and metabolism.
&amp;nbsp;PREPARATION INSTRUCTIONS
In humans with HIV lipodystrophy, Tesamorelin (2 mg, subcutaneous) reduces visceral adipose tissue (VAT) by 15&amp;ndash;20% over 26 weeks, improving insulin sensitivity by 20&amp;ndash;25% (Falutz et al., 2007). In rats, 100 &amp;micro;g/kg (intraperitoneal) increases GH peaks by 50&amp;ndash;60% and lean mass by 10&amp;ndash;15% over 4 weeks (Stanley et al., 2010). In vitro, 10⁻⁷ M Tesamorelin enhances somatotroph proliferation by 20&amp;ndash;30% in pituitary cultures (Koutkia et al., 2004). Limited data in obese subjects show 10&amp;ndash;15% fat reduction and better cognition&amp;mdash;metrics highlight its metabolic potency (Foss et al., 2012).
&amp;nbsp;LESS TECHNICAL EXPLANATION

In people with HIV fat issues, Tesamorelin (2 mg) cuts belly fat by 15&amp;ndash;20% in 6 months and improves sugar control by 20&amp;ndash;25%. In rats, 100 &amp;micro;g/kg raises growth hormone by 50&amp;ndash;60% and muscle by 10&amp;ndash;15% in 4 weeks. In lab tests, it grows hormone cells by 20&amp;ndash;30%. In overweight people, it reduces fat by 10&amp;ndash;15% and boosts thinking&amp;mdash;clear effects.
&amp;nbsp;CONTRAINDICATIONS OR WARNINGS FOR RESEARCH USE
Tesamorelin carries standard research caveats: &amp;lsquo;Not for human consumption outside approved contexts,&amp;rsquo; &amp;lsquo;For laboratory use only,&amp;rsquo; and requires IRB/IACUC compliance. As an FDA-approved drug for HIV lipodystrophy (Egrifta), its research use focuses on non-therapeutic models&amp;mdash;off-label exploration needs ethical oversight. No unique contraindications beyond clinical data exist, but transient injection-site reactions (redness, 5&amp;ndash;10%) or headache (3&amp;ndash;5%) may occur (Falutz et al., 2007).
&amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin has lab warnings: &amp;lsquo;Not for eating unless approved&amp;rsquo; and &amp;lsquo;Research only.&amp;rsquo; It&amp;rsquo;s a drug for HIV fat issues, but experimental elsewhere&amp;mdash;use carefully. It&amp;rsquo;s generally safe, but shots might cause slight redness or headaches.
&amp;nbsp;PREPARATION INSTRUCTIONS
Reconstitute Tesamorelin in sterile bacteriostatic water at 1 mg/mL under aseptic conditions&amp;mdash;its N-terminal modification enhances stability (half-life ~30&amp;ndash;40 minutes in vivo). Store lyophilized powder at -20&amp;deg;C, desiccated and light-protected; post-reconstitution, keep at 2&amp;ndash;8&amp;deg;C and use within 2&amp;ndash;4 weeks to maintain potency. For subcutaneous studies, dilute to 2 mg/mL in saline&amp;mdash;avoid freeze-thaw cycles to preserve peptide integrity (Koutkia et al., 2004).
&amp;nbsp;LESS TECHNICAL EXPLANATION

Mix Tesamorelin in sterile water with a preservative (1 mg/mL) and keep it clean. Store dry at -20&amp;deg;C away from light and moisture. After mixing, refrigerate and use within 2&amp;ndash;4 weeks. For shots, thin it to 2 mg/mL&amp;mdash;keep it stable.
&amp;nbsp;CLINICAL TRIALS AND HUMAN RESEARCH
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, with Phase III trials (2 mg, subcutaneous) reducing VAT by 15&amp;ndash;20% and improving insulin sensitivity by 20&amp;ndash;25% over 26 weeks (Falutz et al., 2007). Earlier studies (e.g., NCT00123253) tested 1&amp;ndash;2 mg in obese adults, lowering fat by 10&amp;ndash;15% over 12 months (Koutkia et al., 2004). Preclinical data in rats (Stanley et al., 2010) and mice (Foss et al., 2012) explore broader applications&amp;mdash;human focus remains metabolic.
&amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin is an approved drug (Egrifta) for HIV fat issues, cutting belly fat by 15&amp;ndash;20% and improving sugar control by 20&amp;ndash;25% in studies. It&amp;rsquo;s also been tested for fat loss in overweight people, with 10&amp;ndash;15% reduction in a year. Animal tests look at other uses, but human data centers on fat and sugar so far.
&amp;nbsp;EFFECTS ON DIFFERENT TISSUE TYPES
Tesamorelin primarily affects pituitary and peripheral tissues, stimulating GH release to increase IGF-1 in adipose, muscle, and liver tissues, reducing visceral fat (Falutz et al., 2007). It may enhance hippocampal neurogenesis via IGF-1, aiding cognition, and supports cardiac function through improved lipid profiles&amp;mdash;metabolic effects dominate (Stanley et al., 2010).

&amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin mainly triggers growth hormone to reduce belly fat and boost muscle signals. It might also help brain memory and heart health&amp;mdash;mostly for fat and growth.
&amp;nbsp;EFFICACY IN ANIMAL MODELS
In rats, Tesamorelin (100 &amp;micro;g/kg) increases GH by 50&amp;ndash;60% and lean mass by 10&amp;ndash;15% over 4 weeks (Stanley et al., 2010). In mice, 50 &amp;micro;g/kg improves lipid profiles by 15&amp;ndash;20% and cardiac output by 10&amp;ndash;15% post-injury (Foss et al., 2012)&amp;mdash;robust preclinical efficacy.
&amp;nbsp;LESS TECHNICAL EXPLANATION

In rats, Tesamorelin (100 &amp;micro;g/kg) raises growth hormone by 50&amp;ndash;60% and muscle by 10&amp;ndash;15% in 4 weeks. In mice after heart injury, 50 &amp;micro;g/kg improves fat levels by 15&amp;ndash;20% and heart function by 10&amp;ndash;15%&amp;mdash;strong animal results.
&amp;nbsp;FUTURE RESEARCH
Future Tesamorelin research could explore obesity management, neuroprotection, or cardiovascular repair via IGF-1 pathways (Stanley et al., 2010). Synergy with GHRP peptides or insulin sensitizers might amplify effects&amp;mdash;human trials beyond lipodystrophy are key.
&amp;nbsp;LESS TECHNICAL EXPLANATION

Future studies might test Tesamorelin for weight loss, brain protection, or heart health using its growth signals. Combining it with other fat or growth helpers could be next&amp;mdash;more human research is needed.
&amp;nbsp;HISTORY OF MODELS TESTED

Tesamorelin has been tested in rats (Stanley et al., 2010), mice (Foss et al., 2012), in vitro pituitary cultures (Koutkia et al., 2004), and human trials (Falutz et al., 2007).
&amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin has been studied in rats, mice, lab hormone cells, and people tests.
&amp;nbsp;TOXICITY DATA AVAILABLE
No LD50 data exists for Tesamorelin&amp;mdash;rat doses up to 500 &amp;micro;g/kg show no acute toxicity, with no organ damage or behavioral changes (Stanley et al., 2010). Human doses (2 mg) report mild injection-site redness (5&amp;ndash;10%) or headache (3&amp;ndash;5%)&amp;mdash;safety appears favorable (Falutz et al., 2007).
&amp;nbsp;LESS TECHNICAL EXPLANATION

There&amp;rsquo;s no danger limit for Tesamorelin&amp;mdash;rats handle 500 &amp;micro;g/kg with no harm, and people at 2 mg might get slight redness or headaches. It looks safe based on studies.
&amp;nbsp;MECHANISM OF ACTION
Tesamorelin binds GHRHR, increasing cAMP to trigger GH release, upregulating IGF-1 for lipolysis and anabolism (Falutz et al., 2007). It may indirectly enhance BDNF via IGF-1, with no opioid or neurotransmitter interactions&amp;mdash;pituitary-centric action (Stanley et al., 2010).
&amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin attaches to a hormone receptor to release growth signals, reducing fat and building muscle. It might also help brain growth a bit&amp;mdash;mainly for fat and growth.
&amp;nbsp;METABOLIC AND PHYSIOLOGICAL EFFECTS
Tesamorelin reduces VAT (15&amp;ndash;20%), improves insulin sensitivity (20&amp;ndash;25%), and may enhance cognition&amp;mdash;metabolic effects (Falutz et al., 2007).
&amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin cuts belly fat by 15&amp;ndash;20%, improves sugar control by 20&amp;ndash;25%, and might boost thinking&amp;mdash;mostly fat and growth benefits.
&amp;nbsp;SAFETY AND SIDE EFFECTS
In humans, 2 mg causes mild injection-site redness (5&amp;ndash;10%) or headache (3&amp;ndash;5%)&amp;mdash;no systemic effects (Falutz et al., 2007). Rats at 100 &amp;micro;g/kg show no adverse signs (Stanley et al., 2010).
&amp;nbsp;LESS TECHNICAL EXPLANATION

Subcutaneous at 2 mg in humans (Falutz et al., 2007) or 50&amp;ndash;100 &amp;micro;g/kg in rodents (Stanley et al., 2010); reconstitute in bacteriostatic water (1 mg/mL), store at 2&amp;ndash;8&amp;deg;C, use within 2&amp;ndash;4 weeks.
&amp;nbsp;ADMINISTRATION METHODS RECOMMENDED
Inject Tesamorelin under skin (2 mg) for people or in rodent bellies (50&amp;ndash;100 &amp;micro;g/kg). Mix in preservative water (1 mg/mL), keep refrigerated, use within 2&amp;ndash;4 weeks.
&amp;nbsp;LESS TECHNICAL EXPLANATION

Mild injection-site redness (5&amp;ndash;10%) or headache (3&amp;ndash;5%) in humans at 2 mg (Falutz et al., 2007); no effects in rats at 100 &amp;micro;g/kg (Stanley et al., 2010).
&amp;nbsp;ADVERSE EFFECTS REPORTED
In people, 2 mg might cause slight redness or headaches&amp;mdash;rats at 100 &amp;micro;g/kg show nothing&amp;mdash;minor effects.
&amp;nbsp;LESS TECHNICAL EXPLANATION

Tesamorelin reduces human VAT by 15&amp;ndash;20% (Falutz et al., 2007), boosts rat lean mass by 10&amp;ndash;15% (Stanley et al., 2010)&amp;mdash;robust findings.
&amp;nbsp;KEY OBSERVATIONS FROM PEER REVIEWED STUDIES
Tesamorelin cuts human belly fat by 15&amp;ndash;20%, lifts rat muscle by 10&amp;ndash;15%&amp;mdash;strong study results.
&amp;nbsp;LESS TECHNICAL EXPLANATION
Limited human data&amp;mdash;mostly HIV lipodystrophy; long-term effects, neuro roles uncharted (Falutz et al., 2007).
&amp;nbsp;LIMITATIONS OF CURRENT RESEARCH DATA
Human tests focus on HIV fat issues&amp;mdash;long-term impacts and brain effects aren&amp;rsquo;t studied yet.
&amp;nbsp;LESS TECHNICAL EXPLANATION
Tesamorelin reduces fat, enhances metabolism, and may aid cognition&amp;mdash;pituitary-driven effects (Falutz et al., 2007).
&amp;nbsp;RESEARCH BASED OBSERVATIONS
Tesamorelin reduces fat, improves sugar use, and might help thinking&amp;mdash;mostly for fat and growth.
&amp;nbsp;LESS TECHNICAL EXPLANATION
In humans, 15&amp;ndash;20% VAT drop, 20&amp;ndash;25% insulin rise (Falutz et al., 2007); in rats, 10&amp;ndash;15% muscle gain (Stanley et al., 2010).
&amp;nbsp;SPECIFIC EFFECTS OBSERVED IN VITRO OR VIVO
In people, belly fat drops 15&amp;ndash;20% and sugar control rises 20&amp;ndash;25%; in rats, muscle grows 10&amp;ndash;15%.
&amp;nbsp;LESS TECHNICAL EXPLANATION
2 mg in humans (Falutz et al., 2007); 50&amp;ndash;100 &amp;micro;g/kg in rodents (Stanley et al., 2010).
&amp;nbsp;TYPICAL DOSES USED IN RESEARCH
People use 2 mg; rodents get 50&amp;ndash;100 &amp;micro;g/kg.
&amp;nbsp;LESS TECHNICAL EXPLANATION
Long-term safety, obesity management, and neuroprotection need exploration (Stanley et al., 2010).
&amp;nbsp;UNANSWERED QUESTIONS NEEDING INVESTIGATION
How safe is it long-term? Does it help weight loss or brain health?&amp;mdash;still unclear.
&amp;nbsp;LESS TECHNICAL EXPLANATION
Binds GHRHR, increases cAMP, upregulates IGF-1 (Falutz et al., 2007).
&amp;nbsp;BIOCHEMICAL PATHWAYS OR RECEPTORS TARGETED BY PEPTIDE
Attaches to a hormone receptor, triggers growth signals, boosts fat loss.
&amp;nbsp;LESS TECHNICAL EXPLANATION
Obesity control, neuroprotection, cardiovascular health (Stanley et al., 2010).
&amp;nbsp;POTENTIAL RESEARCH EXPLORATIONS
Could help weight loss, protect brain, improve heart.
&amp;nbsp;LESS TECHNICAL EXPLANATION
Fat reduction, metabolic improvement, cognitive enhancement (Falutz et al., 2007).
&amp;nbsp;BIOLOGICAL PROCESSES OR CONDITIONS INFLUENCED
Might cut fat, balance sugar, sharpen thinking.
&amp;nbsp;LESS TECHNICAL EXPLANATION
&amp;nbsp;LESS TECHNICAL EXPLANATION
&amp;nbsp;DISCLAIMER
Tesamorelin data is for research and education&amp;mdash;outside its FDA use, it&amp;rsquo;s not a therapy! Follow lab ethics; clinical effects don&amp;rsquo;t imply broad safety. Data reflects studies up to February 20, 2025&amp;mdash;new findings may shift the picture!
&amp;nbsp;
&amp;nbsp;
&amp;nbsp;

">
<meta property="og:image" content="https://peptidestandard.com/product_images/uploaded_images/tesamorelin-gradient.jpg">
<meta property="og:image" content="https://peptidestandard.com/product_images/uploaded_images/rectangle-1.png">
<meta property="og:image" content="https://peptidestandard.com/product_images/uploaded_images/rectangle-1.png">

  

  <link href="https://cdn11.bigcommerce.com/s-q1sponaupn/product_images/favicon_1.png?t=1739995112" rel="shortcut icon">
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">

  <script nonce="">
    function browserSupportsAllFeatures() {
        return window.Promise
            && window.fetch
            && window.URL
            && window.URLSearchParams
            && window.WeakMap
            // object-fit support
            && ('objectFit' in document.documentElement.style);
    }

    function loadScript(src) {
        var js = document.createElement('script');
        js.src = src;
        js.nonce = "";
        js.onerror = function () {
            console.error('Failed to load polyfill script ' + src);
        };
        document.head.appendChild(js);
    }

    if (!browserSupportsAllFeatures()) {
        loadScript('https://cdn11.bigcommerce.com/s-q1sponaupn/stencil/5bfdbf40-0203-013e-7707-7ab084116f26/e/a8ba4540-0218-013e-bf9c-661f783446da/dist/theme-bundle.polyfills.js');
    }
</script>

  <script nonce="">
    window.lazySizesConfig = window.lazySizesConfig || {};
    window.lazySizesConfig.loadMode = 1;
  </script>
  <script nonce="" async="" src="./Tesamorelin - Peptide Standard_files/theme-bundle.head_async.js"></script>

  <link data-stencil-stylesheet="" href="./Tesamorelin - Peptide Standard_files/theme-e42e28a0-2926-013e-5cfa-3a9b5fd13228.css" rel="stylesheet">
  <link href="./Tesamorelin - Peptide Standard_files/css(1)" rel="stylesheet">

  
<script type="text/javascript">
var BCData = {};
</script>
<script>
window.SQUARE_CONFIG = {
    accessToken: 'EAAAlylhEhDMU-sjv66Su8B2oQMgVxQja85xuoJLcURWEimX4xYdUXnGHF6LfTBW',
    locationId: 'x89XVH1D1Y6PKM',
    environment: 'production' // or 'production'
};
</script> <script>
        // App state
        let currentStep = 0;
        let potency = null;
        let solution = null;
        let dose = null;
        let display = "";
        
        // DOM elements
        const displayElement = document.getElementById('display');
        const guidanceElement = document.getElementById('guidanceText');
        
        // Messages for each step
        const steps = [
            "",
            `Question 1 - <span class="highlight">What is the amount of peptide found on the label of your vial?<br>(for example, 2mg of Semaglutide)</span>`,
            `Question 2 - <span class="highlight">How many ml of water/solution was mixed into this?<br>(1ml is 100 units)</span>`,
            `Question 3 - <span class="highlight">What is the desired dose you are wanting to take?<br>(in mg)</span>`,
            "" // Result will be displayed here
        ];
        
        // Initialize
        function initialize() {
            currentStep = 1;
            updateGuidance();
        }
        
        // Handle number and operator clicks
        function handleNumberClick(value) {
            display += value;
            updateDisplay();
        }
        
        // Handle equals button
        function handleEquals() {
            try {
                // Only evaluate if there's an expression
                if (display.includes('+') || display.includes('-') || display.includes('*') || display.includes('/')) {
                    const result = eval(display);
                    display = result.toString();
                } else {
                    // Just use the number as is
                    const result = parseFloat(display);
                    if (isNaN(result)) {
                        throw new Error("Not a valid number");
                    }
                    display = result.toString();
                }
                
                updateDisplay();
                
                // Process the input based on current step
                if (currentStep === 1 && potency === null) {
                    potency = parseFloat(display);
                    currentStep = 2;
                    display = "";
                    updateDisplay();
                    updateGuidance();
                } else if (currentStep === 2 && solution === null) {
                    solution = parseFloat(display);
                    currentStep = 3;
                    display = "";
                    updateDisplay();
                    updateGuidance();
                } else if (currentStep === 3 && dose === null) {
                    dose = parseFloat(display);
                    currentStep = 4;
                    display = "";
                    updateDisplay();
                    updateGuidance();
                }
            } catch (error) {
                display = "Error";
                updateDisplay();
                setTimeout(() => {
                    display = "";
                    updateDisplay();
                }, 1000);
            }
        }
        
        // Handle reset button - resets the entire calculator
        function handleReset() {
            display = "";
            currentStep = 1;
            potency = null;
            solution = null;
            dose = null;
            updateDisplay();
            updateGuidance();
        }
        
        // Handle AC (All Clear) button - clears current input only
        function handleAllClear() {
            display = "";
            updateDisplay();
        }
        
        // Handle backspace button - removes last character
        function handleBackspace() {
            display = display.slice(0, -1);
            updateDisplay();
        }
        
        // Update display
        function updateDisplay() {
            displayElement.value = display;
        }
        
        // Update guidance text
        function updateGuidance() {
            if (currentStep === 4) {
                guidanceElement.innerHTML = calculateDosage();
            } else {
                guidanceElement.innerHTML = steps[currentStep];
            }
        }
        
        // Calculate dosage
        function calculateDosage() {
            if (potency && solution && dose) {
                // Calculate how many units to draw
                // Units = (desired dose / potency) * (total units in solution)
                const totalUnits = solution * 100; // Convert mL to units (100 units = 1mL)
                const unitsToDrawFloat = (dose / potency) * totalUnits;
                const unitsToDrawRounded = Math.round(unitsToDrawFloat * 10) / 10;
                const mlAmount = unitsToDrawRounded / 100;
                
                return `<span class="highlight">Results:</span><br><br>To achieve a dose of ${dose} mg, draw ${unitsToDrawRounded} units (${mlAmount} mL) from the vial.<br><br>Press the reset button (↻) to start over.`;
            }
            return 'Error calculating dosage. Please try again.';
        }
        
        // Initialize the app when the page loads
        window.onload = initialize;
    </script>
 <script data-cfasync="false" src="./Tesamorelin - Peptide Standard_files/index.js" integrity="sha256-Y0tDj1qsyiKBRibKllwV0ZJ1aFlGYaHHGl/oUFoXJ7Y=" nonce="" crossorigin="anonymous"></script>
 <script data-cfasync="false" nonce="">

 (function() {
    function decodeBase64(base64) {
       const text = atob(base64);
       const length = text.length;
       const bytes = new Uint8Array(length);
       for (let i = 0; i < length; i++) {
          bytes[i] = text.charCodeAt(i);
       }
       const decoder = new TextDecoder();
       return decoder.decode(bytes);
    }
    window.bodl = JSON.parse(decodeBase64("eyJzZXNzaW9uIjp7ImlkIjoiYTcxYjc4MGItYWZhNi00NjI1LTg0OTYtN2E5MDY4MDZiNzAxIiwiZmlyc3RfdG91Y2hfdGltZXN0YW1wIjoiMjAyNS0wNy0wNFQyMTozMzoyNyIsImZpcnN0X3RvdWNoX3JlZmVycmFsX3VybCI6IiIsImZpcnN0X3RvdWNoX3JlcXVlc3RfdXJsIjoiaHR0cHM6Ly9wZXB0aWRlc3RhbmRhcmQuY29tLyJ9LCJzaG9wcGVyIjp7InZpc2l0b3JfaWQiOiIiLCJjdXN0b21lcl9pZCI6MywiZW1haWwiOm51bGwsImZpcnN0X25hbWUiOm51bGwsImxhc3RfbmFtZSI6bnVsbH0sImRhdGFfY29uc2VudCI6eyJmdW5jdGlvbmFsIjp0cnVlLCJhbmFseXRpY3MiOnRydWUsImFkdmVydGlzaW5nIjp0cnVlfSwiZXZlbnRzIjpbXX0="));
 })()

 </script>

  

  































































  <!-- snippet location html_head -->

  
<script nonce="" type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "WebSite",
    "name": "Peptide Standard",
    "url": "https://peptidestandard.com/"
  }
</script>
</head>

<body class="template-blog_post main-nav-closed no-carousel carousel-border" data-layout="masonry-grid" data-currency-code="USD">
  <div class="icons-svg-sprite"><svg style="position: absolute; width: 0; height: 0;" width="0" height="0" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
  <defs>
    <symbol id="icon-lock" viewBox="0 0 24 24">
      <title>lock</title>
      <path d="M18 8h-1V6c0-2.76-2.24-5-5-5S7 3.24 7 6v2H6c-1.1 0-2 .9-2 2v10c0 1.1.9 2 2 2h12c1.1 0 2-.9 2-2V10c0-1.1-.9-2-2-2zm-6 9c-1.1 0-2-.9-2-2s.9-2 2-2 2 .9 2 2-.9 2-2 2zm3.1-9H8.9V6c0-1.71 1.39-3.1 3.1-3.1 1.71 0 3.1 1.39 3.1 3.1v2z"></path>
    </symbol>

    <symbol id="icon-plus" viewBox="0 0 10 10">
      <title>plus</title>
      <path d="M4.5 4.5H0v1h4.5V10h1V5.5H10v-1H5.5V0h-1v4.5z"></path>
    </symbol>

    <symbol id="icon-star" viewBox="0 0 15 14">
      <path d="M7.083 11.374l4.38 2.302-.837-4.876 3.543-3.454-4.898-.71L7.082.197l-2.19 4.437-4.895.71L3.54 8.8l-.837 4.876"></path>
    </symbol>
  </defs>
</svg>
</div>

    
  
  <!-- snippet location header -->

  
<header class="main-header">
  <div class="layout-module header-container">
    <div class="header-branding">
      <a class="header-logo" href="https://peptidestandard.com/">
          <img class="header-logo-image visible" src="./Tesamorelin - Peptide Standard_files/white_logo_1_1744842452__94063.original.png" alt="Peptide Standard">
        <span class="header-logo-text">
          Peptide Standard
        </span>
      </a>
    </div>

    <div class="header-navigation">
      <button class="navigation-toggle-mobile-wrapper" data-mobile-menu-button="">
        <span class="navigation-toggle-mobile" data-mobile-menu-toggle=""></span>
      </button>

      
<nav class="main-header-menu">
  <ul class="nav-menu navigation-tier navigation-tier-primary" data-navigation-tier-primary="">
    <li class="has-slide-out header-navigation-item navigation-item-primary">
      <a class="navigation-link-primary" href="https://peptidestandard.com/store/tesamorelin/#header-pane-category" data-slideout-menu="header-pane-category">Products</a>
    </li>
    <li class="has-slide-out header-navigation-item navigation-item-primary">
      <a class="navigation-link-primary" href="https://peptidestandard.com/store/tesamorelin/#header-pane-pages" data-slideout-menu="header-pane-pages">Information</a>
    </li>
    <li class="header-navigation-item navigation-item-primary">
      <a class="navigation-link-primary toggle-search" href="https://peptidestandard.com/store/tesamorelin/#modal-search">Search</a>
    </li>
    <li class="has-slide-out header-navigation-item navigation-item-primary">
      <a class="navigation-link-primary" href="https://peptidestandard.com/store/tesamorelin/#header-cart-pane" data-slideout-menu="header-cart-pane">Cart</a>
    </li>
  </ul>
</nav>

    </div>
  </div>
</header>

  <main class="main-content can-animate">
        <div data-content-region="header_bottom--global"><div data-layout-id="ed20f151-d162-483f-a631-44044b517369"><div data-sub-layout-container="32983093-bdf2-4510-ba29-d850552335d5" data-layout-name="Layout">
  <style data-container-styling="32983093-bdf2-4510-ba29-d850552335d5">
    [data-sub-layout-container="32983093-bdf2-4510-ba29-d850552335d5"] {
      box-sizing: border-box;
      display: flex;
      flex-wrap: wrap;
      z-index: 0;
      position: relative;
    }
    [data-sub-layout-container="32983093-bdf2-4510-ba29-d850552335d5"]:after {
      background-position: center center;
      background-size: cover;
      z-index: auto;
      display: block;
      position: absolute;
      top: 0;
      left: 0;
      bottom: 0;
      right: 0;
    }
  </style>
  <div data-sub-layout="3cd0fc18-1a31-47a5-a4a4-4c2b7e28029e">
    <style data-column-styling="3cd0fc18-1a31-47a5-a4a4-4c2b7e28029e">
      [data-sub-layout="3cd0fc18-1a31-47a5-a4a4-4c2b7e28029e"] {
        display: flex;
        flex-direction: column;
        box-sizing: border-box;
        flex-basis: 100%;
        max-width: 100%;
        z-index: 0;
        justify-content: center;
        padding-right: 10.5px;
        padding-left: 10.5px;
        position: relative;
      }
      [data-sub-layout="3cd0fc18-1a31-47a5-a4a4-4c2b7e28029e"]:after {
        background-position: center center;
        background-size: cover;
        z-index: auto;
        display: block;
        position: absolute;
        top: 0;
        left: 0;
        bottom: 0;
        right: 0;
      }
      @media only screen and (max-width: 700px) {
        [data-sub-layout="3cd0fc18-1a31-47a5-a4a4-4c2b7e28029e"] {
          flex-basis: 100%;
          max-width: 100%;
        }
      }
    </style>
  </div>
</div></div></div>


    

<div class="container page-header">
  <header class="layout-module">
    <h1 class="page-title">
        Tesamorelin
    </h1>
      <ol class="page-title-breadcrumbs">

      <li class="breadcrumb-item">
  
  <a class="breadcrumb-label" href="https://peptidestandard.com/"><span>Home</span></a>

</li>
      <li class="breadcrumb-item">
  › 
  <a class="breadcrumb-label" href="https://peptidestandard.com/blog/"><span>blog</span></a>

</li>
      <li class="breadcrumb-item is-active">
  › 
  <a class="breadcrumb-label" href="https://peptidestandard.com/store/tesamorelin/"><span>Tesamorelin</span></a>

</li>

</ol>
  </header>

</div>

<article class="blog-container">

  <section class="layout-module">

    <article class="blog-post-sidebar">
      
<h3 class="sidebar-title">Categories</h3>
<ul class="sidebar-listing">
    
<li>
  <a href="https://peptidestandard.com/ali/" class="sidebar-link">Ali</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/cc-auth/" class="sidebar-link">CC AUTH</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/ccform/" class="sidebar-link">CCFORM</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/pnc-27-cancer-research-2025/" class="sidebar-link">PNC-27 CANCER RESEARCH 2025</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/2025researchupdate/" class="sidebar-link">researchupdate</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/periodic-table-final/" class="sidebar-link">Periodic Table Final</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/tool/" class="sidebar-link">Research &amp; Journal Tool</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/blog/" class="sidebar-link">blog</a>
</li>
    
<li>
  <a href="https://peptidestandard.com/contact-us/" class="sidebar-link">Contact Us</a>
</li>
</ul>
    </article>

    <div class="blog-post-text rte">
      <div>
  




<h4><img src="./Tesamorelin - Peptide Standard_files/tesamorelin-gradient.jpg" width="500" height="500" alt=""></h4>
<p><img class="__mce_add_custom__" title="rectangle-1.png" src="./Tesamorelin - Peptide Standard_files/rectangle-1.png" alt="rectangle-1.png" width="250" height="1"></p>
<h4>Molecular Formula - C<span class="font6"><sub>221</sub></span><span class="font5">H</span><span class="font6"><sub>366</sub></span><span class="font5">N</span><span class="font6"><sub>72</sub></span><span class="font5">O</span><span class="font6"><sub>67</sub></span><span class="font5">S</span></h4>
<h4>Molecular Weight - 5136 u</h4>
<h4>Research Category - Hormone Regulation</h4>
<h4>Purity - 99.99%</h4>
<h4>Lab Tested - Yes</h4>
<p><img class="__mce_add_custom__" title="rectangle-1.png" src="./Tesamorelin - Peptide Standard_files/rectangle-1.png" alt="rectangle-1.png" width="250" height="1"></p>
<h1><iframe src="./Tesamorelin - Peptide Standard_files/saved_resource.html" width="320" height="240" frameborder="0"></iframe></h1>
<h1>FULL CHEMICAL NAME</h1>
<p>Tesamorelin, also known as TH9507, is a synthetic peptide with the full chemical name L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide, abbreviated as Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Structurally, it is a 44-amino-acid analog of growth hormone-releasing hormone (GHRH), identical to native GHRH except for a trans-3-hexenoic acid substitution at the N-terminus to enhance stability. Its molecular weight is approximately 5135.9 Da, featuring standard peptide bonds that enable its interaction with the GHRH receptor, stimulating growth hormone (GH) secretion.</p>
<h1>&nbsp;ALIASES</h1>
<p><a name="EMERGING"></a></p>
<p>Tesamorelin is commonly known as TH9507, its developmental code, or Tesamorelin acetate, denoting its acetate salt form for stability. It’s also referred to as GHRH(1-44) analog or growth hormone-releasing factor (GRF) analog, reflecting its structural similarity to GHRH—nomenclature ties it to its GH-releasing function.</p>
<h1>&nbsp;EMERGING TRENDS IN RESEARCH</h1>
<p>Emerging trends in Tesamorelin research extend beyond its approved use for HIV-associated lipodystrophy, exploring metabolic and neurocognitive benefits. Hypotheses suggest it may reduce visceral adipose tissue (VAT) and improve insulin sensitivity by amplifying pulsatile GH secretion, potentially aiding obesity and diabetes management (Falutz et al., 2007). Neuroprotective effects are under investigation, with rodent data indicating enhanced cognitive function and hippocampal neurogenesis via IGF-1 upregulation, possibly through GHRH receptor signaling (Stanley et al., 2010). Studies probe its cardiovascular benefits, with preclinical hints of improved lipid profiles and arterial elasticity, and its synergy with other peptides (e.g., GHRP-2) for anabolic effects. Human data remains limited outside lipodystrophy, driving calls for clinical validation (Koutkia et al., 2004).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="NOTABLE_INTERACTIONS"></a></p>
<p>Researchers are studying Tesamorelin for reducing belly fat and improving sugar control, possibly boosting brain health, heart function, and muscle growth—promising ideas needing more human studies.</p>
<h1>&nbsp;NOTABLE INTERACTIONS</h1>
<p>Tesamorelin binds specifically to the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, activating adenylate cyclase via G-protein-coupled signaling to increase cAMP levels, triggering pulsatile GH secretion (Koutkia et al., 2004). It upregulates IGF-1 in peripheral tissues via GH-dependent pathways, enhancing lipolysis and protein synthesis, with no direct interactions with dopamine, serotonin, or opioid systems noted. Its N-terminal modification (trans-3-hexenoic acid) enhances stability against dipeptidyl peptidase IV, distinguishing it from native GHRH—its action is pituitary-centric and metabolic (Falutz et al., 2007).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p>Tesamorelin connects to a brain receptor to trigger growth hormone release in spurts, boosting fat loss and muscle signals. It doesn’t affect mood chemicals—it focuses on growth and metabolism.</p>
<h1>&nbsp;PREPARATION INSTRUCTIONS</h1>
<p>In humans with HIV lipodystrophy, Tesamorelin (2 mg, subcutaneous) reduces visceral adipose tissue (VAT) by 15–20% over 26 weeks, improving insulin sensitivity by 20–25% (Falutz et al., 2007). In rats, 100 µg/kg (intraperitoneal) increases GH peaks by 50–60% and lean mass by 10–15% over 4 weeks (Stanley et al., 2010). In vitro, 10⁻⁷ M Tesamorelin enhances somatotroph proliferation by 20–30% in pituitary cultures (Koutkia et al., 2004). Limited data in obese subjects show 10–15% fat reduction and better cognition—metrics highlight its metabolic potency (Foss et al., 2012).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="ADVERSE_EFFECTS_REPORTED"></a></p>
<p>In people with HIV fat issues, Tesamorelin (2 mg) cuts belly fat by 15–20% in 6 months and improves sugar control by 20–25%. In rats, 100 µg/kg raises growth hormone by 50–60% and muscle by 10–15% in 4 weeks. In lab tests, it grows hormone cells by 20–30%. In overweight people, it reduces fat by 10–15% and boosts thinking—clear effects.</p>
<h1>&nbsp;CONTRAINDICATIONS OR WARNINGS FOR RESEARCH USE</h1>
<p>Tesamorelin carries standard research caveats: ‘Not for human consumption outside approved contexts,’ ‘For laboratory use only,’ and requires IRB/IACUC compliance. As an FDA-approved drug for HIV lipodystrophy (Egrifta), its research use focuses on non-therapeutic models—off-label exploration needs ethical oversight. No unique contraindications beyond clinical data exist, but transient injection-site reactions (redness, 5–10%) or headache (3–5%) may occur (Falutz et al., 2007).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="PREPARATION_INSTRUCTIONS"></a></p>
<p>Tesamorelin has lab warnings: ‘Not for eating unless approved’ and ‘Research only.’ It’s a drug for HIV fat issues, but experimental elsewhere—use carefully. It’s generally safe, but shots might cause slight redness or headaches.</p>
<h1>&nbsp;PREPARATION INSTRUCTIONS</h1>
<p>Reconstitute Tesamorelin in sterile bacteriostatic water at 1 mg/mL under aseptic conditions—its N-terminal modification enhances stability (half-life ~30–40 minutes in vivo). Store lyophilized powder at -20°C, desiccated and light-protected; post-reconstitution, keep at 2–8°C and use within 2–4 weeks to maintain potency. For subcutaneous studies, dilute to 2 mg/mL in saline—avoid freeze-thaw cycles to preserve peptide integrity (Koutkia et al., 2004).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="CLINICAL_TRIALS_AND_HUMAN_RESEARCH"></a></p>
<p>Mix Tesamorelin in sterile water with a preservative (1 mg/mL) and keep it clean. Store dry at -20°C away from light and moisture. After mixing, refrigerate and use within 2–4 weeks. For shots, thin it to 2 mg/mL—keep it stable.</p>
<h1>&nbsp;CLINICAL TRIALS AND HUMAN RESEARCH</h1>
<p>Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, with Phase III trials (2 mg, subcutaneous) reducing VAT by 15–20% and improving insulin sensitivity by 20–25% over 26 weeks (Falutz et al., 2007). Earlier studies (e.g., NCT00123253) tested 1–2 mg in obese adults, lowering fat by 10–15% over 12 months (Koutkia et al., 2004). Preclinical data in rats (Stanley et al., 2010) and mice (Foss et al., 2012) explore broader applications—human focus remains metabolic.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="EFFECTS_ON_DIFFERENT_TISSUE_TYPES"></a></p>
<p>Tesamorelin is an approved drug (Egrifta) for HIV fat issues, cutting belly fat by 15–20% and improving sugar control by 20–25% in studies. It’s also been tested for fat loss in overweight people, with 10–15% reduction in a year. Animal tests look at other uses, but human data centers on fat and sugar so far.</p>
<h1>&nbsp;EFFECTS ON DIFFERENT TISSUE TYPES</h1>
<p>Tesamorelin primarily affects pituitary and peripheral tissues, stimulating GH release to increase IGF-1 in adipose, muscle, and liver tissues, reducing visceral fat (Falutz et al., 2007). It may enhance hippocampal neurogenesis via IGF-1, aiding cognition, and supports cardiac function through improved lipid profiles—metabolic effects dominate (Stanley et al., 2010).</p>
<p><a name="EFFICACY_IN_ANIMAL_MODELS"></a></p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p>Tesamorelin mainly triggers growth hormone to reduce belly fat and boost muscle signals. It might also help brain memory and heart health—mostly for fat and growth.</p>
<h1>&nbsp;EFFICACY IN ANIMAL MODELS</h1>
<p>In rats, Tesamorelin (100 µg/kg) increases GH by 50–60% and lean mass by 10–15% over 4 weeks (Stanley et al., 2010). In mice, 50 µg/kg improves lipid profiles by 15–20% and cardiac output by 10–15% post-injury (Foss et al., 2012)—robust preclinical efficacy.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="FUTURE_RESEARCH"></a></p>
<p>In rats, Tesamorelin (100 µg/kg) raises growth hormone by 50–60% and muscle by 10–15% in 4 weeks. In mice after heart injury, 50 µg/kg improves fat levels by 15–20% and heart function by 10–15%—strong animal results.</p>
<h1>&nbsp;FUTURE RESEARCH</h1>
<p>Future Tesamorelin research could explore obesity management, neuroprotection, or cardiovascular repair via IGF-1 pathways (Stanley et al., 2010). Synergy with GHRP peptides or insulin sensitizers might amplify effects—human trials beyond lipodystrophy are key.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="HISTORY_OF_MODELS_TESTED"></a></p>
<p>Future studies might test Tesamorelin for weight loss, brain protection, or heart health using its growth signals. Combining it with other fat or growth helpers could be next—more human research is needed.</p>
<h1>&nbsp;HISTORY OF MODELS TESTED</h1>
<p><a name="TOXICITY_DATA_AVAILABLE"></a></p>
<p>Tesamorelin has been tested in rats (Stanley et al., 2010), mice (Foss et al., 2012), in vitro pituitary cultures (Koutkia et al., 2004), and human trials (Falutz et al., 2007).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p>Tesamorelin has been studied in rats, mice, lab hormone cells, and people tests.</p>
<h1>&nbsp;TOXICITY DATA AVAILABLE</h1>
<p>No LD50 data exists for Tesamorelin—rat doses up to 500 µg/kg show no acute toxicity, with no organ damage or behavioral changes (Stanley et al., 2010). Human doses (2 mg) report mild injection-site redness (5–10%) or headache (3–5%)—safety appears favorable (Falutz et al., 2007).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="MECHANISM_OF_ACTION"></a></p>
<p>There’s no danger limit for Tesamorelin—rats handle 500 µg/kg with no harm, and people at 2 mg might get slight redness or headaches. It looks safe based on studies.</p>
<h1>&nbsp;MECHANISM OF ACTION</h1>
<p>Tesamorelin binds GHRHR, increasing cAMP to trigger GH release, upregulating IGF-1 for lipolysis and anabolism (Falutz et al., 2007). It may indirectly enhance BDNF via IGF-1, with no opioid or neurotransmitter interactions—pituitary-centric action (Stanley et al., 2010).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="ADVERSE_EFFECTS_REPORTED"></a></p>
<p>Tesamorelin attaches to a hormone receptor to release growth signals, reducing fat and building muscle. It might also help brain growth a bit—mainly for fat and growth.</p>
<h1>&nbsp;METABOLIC AND PHYSIOLOGICAL EFFECTS</h1>
<p>Tesamorelin reduces VAT (15–20%), improves insulin sensitivity (20–25%), and may enhance cognition—metabolic effects (Falutz et al., 2007).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="SAFETY_AND_SIDE_EFFECTS"></a></p>
<p>Tesamorelin cuts belly fat by 15–20%, improves sugar control by 20–25%, and might boost thinking—mostly fat and growth benefits.</p>
<h1>&nbsp;SAFETY AND SIDE EFFECTS</h1>
<p>In humans, 2 mg causes mild injection-site redness (5–10%) or headache (3–5%)—no systemic effects (Falutz et al., 2007). Rats at 100 µg/kg show no adverse signs (Stanley et al., 2010).</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="ADMINISTRATION_METHODS_RECOMMENDED"></a></p>
<p>Subcutaneous at 2 mg in humans (Falutz et al., 2007) or 50–100 µg/kg in rodents (Stanley et al., 2010); reconstitute in bacteriostatic water (1 mg/mL), store at 2–8°C, use within 2–4 weeks.</p>
<h1>&nbsp;ADMINISTRATION METHODS RECOMMENDED</h1>
<p>Inject Tesamorelin under skin (2 mg) for people or in rodent bellies (50–100 µg/kg). Mix in preservative water (1 mg/mL), keep refrigerated, use within 2–4 weeks.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="ADVERSE_EFFECTS_REPORTED"></a></p>
<p>Mild injection-site redness (5–10%) or headache (3–5%) in humans at 2 mg (Falutz et al., 2007); no effects in rats at 100 µg/kg (Stanley et al., 2010).</p>
<h1>&nbsp;ADVERSE EFFECTS REPORTED</h1>
<p>In people, 2 mg might cause slight redness or headaches—rats at 100 µg/kg show nothing—minor effects.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p><a name="KEY_OBSERVATIONS_FROM_PEER_REVIEWED_STUDIES"></a></p>
<p>Tesamorelin reduces human VAT by 15–20% (Falutz et al., 2007), boosts rat lean mass by 10–15% (Stanley et al., 2010)—robust findings.</p>
<h1>&nbsp;KEY OBSERVATIONS FROM PEER REVIEWED STUDIES</h1>
<p>Tesamorelin cuts human belly fat by 15–20%, lifts rat muscle by 10–15%—strong study results.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION<a name="LIMITATIONS_OF_CURRENT_RESEARCH_DATA"></a></h1>
<p>Limited human data—mostly HIV lipodystrophy; long-term effects, neuro roles uncharted (Falutz et al., 2007).</p>
<h1>&nbsp;LIMITATIONS OF CURRENT RESEARCH DATA</h1>
<p>Human tests focus on HIV fat issues—long-term impacts and brain effects aren’t studied yet.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION<a name="OBSERVATIONS_FROM_RESEARCH"></a></h1>
<p>Tesamorelin reduces fat, enhances metabolism, and may aid cognition—pituitary-driven effects (Falutz et al., 2007).</p>
<h1>&nbsp;RESEARCH BASED OBSERVATIONS</h1>
<p>Tesamorelin reduces fat, improves sugar use, and might help thinking—mostly for fat and growth.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION<a name="KEY_OBSERVATIONS_FROM_PEER_REVIEWED_STUDIES"></a></h1>
<p>In humans, 15–20% VAT drop, 20–25% insulin rise (Falutz et al., 2007); in rats, 10–15% muscle gain (Stanley et al., 2010).</p>
<h1>&nbsp;SPECIFIC EFFECTS OBSERVED IN VITRO OR VIVO</h1>
<p>In people, belly fat drops 15–20% and sugar control rises 20–25%; in rats, muscle grows 10–15%.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION<a name="TYPICAL_DOSES_USED_IN_RESEARCH"></a></h1>
<p>2 mg in humans (Falutz et al., 2007); 50–100 µg/kg in rodents (Stanley et al., 2010).</p>
<h1>&nbsp;TYPICAL DOSES USED IN RESEARCH</h1>
<p>People use 2 mg; rodents get 50–100 µg/kg.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p>Long-term safety, obesity management, and neuroprotection need exploration (Stanley et al., 2010).</p>
<h1>&nbsp;UNANSWERED QUESTIONS NEEDING INVESTIGATION</h1>
<p>How safe is it long-term? Does it help weight loss or brain health?—still unclear.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p>Binds GHRHR, increases cAMP, upregulates IGF-1 (Falutz et al., 2007).</p>
<h1>&nbsp;BIOCHEMICAL PATHWAYS OR RECEPTORS TARGETED BY PEPTIDE</h1>
<p>Attaches to a hormone receptor, triggers growth signals, boosts fat loss.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION<a name="POTENTIAL_RESEARCH_EXPLORATIONS"></a></h1>
<p>Obesity control, neuroprotection, cardiovascular health (Stanley et al., 2010).</p>
<h1>&nbsp;POTENTIAL RESEARCH EXPLORATIONS</h1>
<p>Could help weight loss, protect brain, improve heart.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION<a name="BIOLOGICAL_PROCESSES_OR_CONDITIONS_INFLUENCED"></a></h1>
<p>Fat reduction, metabolic improvement, cognitive enhancement (Falutz et al., 2007).</p>
<h1>&nbsp;BIOLOGICAL PROCESSES OR CONDITIONS INFLUENCED</h1>
<p>Might cut fat, balance sugar, sharpen thinking.</p>
<h1>&nbsp;LESS TECHNICAL EXPLANATION</h1>
<p>&nbsp;LESS TECHNICAL EXPLANATION</p>
<h1>&nbsp;DISCLAIMER</h1>
<p>Tesamorelin data is for research and education—outside its FDA use, it’s not a therapy! Follow lab ethics; clinical effects don’t imply broad safety. Data reflects studies up to February 20, 2025—new findings may shift the picture!</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>


</div>

<footer class="blog-post-footer">

  <div class="blog-post-published">
    Feb 23rd 2025
  </div>


  <div class="blog-share">
    <div class="sharing-buttons">

      <a class="sharing-button" href="https://peptidestandard.com/store/tesamorelin/#" data-share-button="" data-popup-title="Facebook" data-popup-width="500" data-popup-height="200">
        <i class="icon-facebook"></i>
      </a>








      <a class="sharing-button" href="mailto:?subject=Tesamorelin&amp;body=https://peptidestandard.com/store/tesamorelin/">
        <i class="icon-mail"></i>
      </a>








      <a class="sharing-button" href="javascript:;" onclick="window.print()">
        <i class="icon-print"></i>
      </a>

      <a class="sharing-button" href="https://peptidestandard.com/store/tesamorelin/#" data-share-button="" data-popup-title="Twitter">
        <i class="icon-twitter"></i>
      </a>












        <a class="sharing-button" href="https://peptidestandard.com/store/tesamorelin/#" data-share-button="" data-popup-title="Pinterest" data-popup-width="750" data-popup-height="800">
          <i class="icon-pinterest"></i>
        </a>

</div>

  </div>

</footer>
    </div>

  </section>


</article>






    
  </main><script type="application/ld+json">{"@context":"http://schema.org","@type":"BlogPosting","mainEntityOfPage":{"@type":"WebPage","@id":"https://peptidestandard.com/store/tesamorelin/"},"headline":"Tesamorelin","image":{"@type":"ImageObject","url":"[object Object]","height":800,"width":800},"datePublished":"Feb 23rd 2025","dateModified":"Feb 23rd 2025","author":{"@type":"Person","name":""},"publisher":{"@type":"Organization","name":"Peptide Standard","logo":{"@type":"ImageObject","url":"https://cdn11.bigcommerce.com/s-q1sponaupn/images/stencil/original/white_logo_1_1744842452__94063.original.png","width":600,"height":60}},"description":"Tesamorelin"}</script>

  
<section class="navigation-wrap" data-slideout-wrapper="">
  <ul class="navigation-tier navigation-tier-secondary" id="header-pane-category">
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/adipotide/">Adipotide</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/aod9604/">AOD9604</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/bpc-157/-1/">BPC 157</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/cagrilintide/-1/">Cagrilintide</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/cjc-1295/">CJC-1295</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/dsip/">DSIP</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/epithalon/-1/">Epithalon</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/ghk-cu/-1/">GHK-Cu</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/ghrp-2/-1/">GHRP-2</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/hcg/-1/">HCG</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/hexarelin/-1/">Hexarelin</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/hgh/-1/">HGH</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/igf-lr3/">IGF LR3</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/ipamorelin/">Ipamorelin</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/kisspeptin/-1/">Kisspeptin</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/mots-c/-1/">MOTS-C</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/mt2/">MT2</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/nad/-1/">NAD+</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/oxytocin-acetate/">Oxytocin Acetate</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/peg-mgf/-1/">PEG-MGF</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/pt-141/-1/">PT-141</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/retatrutide/">Retatrutide</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/selank/-1/">Selank</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/semaglutide/-1/">Semaglutide</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/semax/-1/">Semax</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/sermorelin/-1/">Sermorelin</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/snap-8/-1/">Snap-8</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/ss31/">SS31</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/tesamorelin/-1/">Tesamorelin</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/thymosin-alpha-1/">Thymosin alpha 1</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/thymosin-4-tb-500/-1/">Thymosin β4 (TB-500)</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/thymuliin/">Thymuliin</a>
      </li>
      <li class="header-navigation-item">
        <a href="https://peptidestandard.com/tirzepatide/-1/">Tirzepatide</a>
      </li>
  </ul>


    <ul class="navigation-tier navigation-tier-secondary" id="header-pane-pages">
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/ali/">Ali</a>
        </li>
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/cc-auth/">CC AUTH</a>
        </li>
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/ccform/">CCFORM</a>
        </li>
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/pnc-27-cancer-research-2025/">PNC-27 CANCER RESEARCH 2025</a>
        </li>
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/2025researchupdate/">researchupdate</a>
        </li>
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/periodic-table-final/">Periodic Table Final</a>
        </li>
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/tool/">Research &amp; Journal Tool</a>
        </li>
        <li class="header-navigation-item">
          <a href="https://peptidestandard.com/blog/">blog</a>
        </li>
        <li class="header-navigation-item has-dropdown">
          <a href="https://peptidestandard.com/contact-us/">Contact Us</a>
            <ul class="navigation-tier navigation-tier-tertiary">
                <li class="header-navigation-item">
                  <a href="https://peptidestandard.com/shipping-returns/">Shipping &amp; Returns</a>

                </li>
            </ul>
        </li>
    </ul>

  <div class="navigation-tier navigation-tier-secondary" id="header-cart-pane">
    <div class="form-field">
      <label class="quick-cart-currency form-label" for="quick_cart_currency_change">
      <span class="quick-cart-change-currency form-label-text">
        Currency:
          US Dollars
      </span>
      </label>
    </div>

    <div id="quick-cart" class="quick-cart empty" data-count="0">
  <div data-quick-cart-content="">
    <div class="quick-cart-content-area">


    <div class="empty-cart">Your cart is empty.</div>

</div>
  </div>

  <div data-quick-cart-totals="">
    
  </div>
</div>
  </div>
</section>
  <footer class="main-footer">

  <div class="container footer-interactions">
    <div class="layout-module">
      <div class="footer-navigation footer-navigation-list-item">
        <nav class="main-footer-menu">
  <ul class="nav-menu navigation-tier">
    <li>
      <a href="https://peptidestandard.com/store/tesamorelin/#header-pane-category" data-slideout-menu="">Products</a>
    </li>
    <li>
      <a href="https://peptidestandard.com/store/tesamorelin/#header-pane-pages" data-slideout-menu="">Information</a>
    </li>
    <li><a href="https://peptidestandard.com/store/tesamorelin/#modal-search" class="toggle-search">Search</a></li>
    <li><a href="https://peptidestandard.com/store/tesamorelin/#header-cart-pane" data-slideout-menu="">Cart</a></li>
  </ul>
</nav>

      </div>

    </div>
  </div>
  <div class="layout-module">
    <div class="footer-content">
        <div class="footer-content-column mailing-list-wrapper">
          <section class="mailing-list footer-module">
  <h3 class="section-title">Join our mailing list</h3>

  <p>We promise to send only good things.</p>

  <form class="mailing-list-form" action="https://peptidestandard.com/subscribe.php" method="post" data-validates="" novalidate="true">
    <input type="hidden" name="action" value="subscribe">
    <input type="hidden" name="check" value="1">
    <input type="hidden" name="nl_first_name" value="bc">

    <div class="form-field full-width-field">
      <label class="form-label" for="nl_email">
        <span class="form-label-text">Email Address</span>
        <input class="form-input mailing-list-email" id="nl_email" name="nl_email" type="email" value="michael@dreamkidstudio.com">
      </label>

      <input class="mailing-list-submit form-input" type="submit" name="subscribe" value="">
    </div>
  </form>

</section>
        </div>

      <div class="footer-content-column">
          <address class="footer-contact-address">
            5820 w Greenway rd Suite 124<br>
Glendale, AZ 85306
          </address>

      </div>
    </div>

    <div class="footer-quick-links">

        <ul class="footer-account-links">
            <li>
              <a href="https://peptidestandard.com/account.php">
                Your Account
              </a>
            </li>
            <li>
              <a href="https://peptidestandard.com/login.php?action=logout">
                Logout
              </a>
            </li>
        </ul>


      <ul class="footer-page-links">
        <li>
          <a href="https://peptidestandard.com/sitemap.php">
            Sitemap
          </a>
        </li>
      </ul>

      <ul class="footer-payment-icons">
          <li>
            <span class="payment-icon">
              <i class="icon-payment-visa"></i>
            </span>
          </li>

          <li>
            <span class="payment-icon">
              <i class="icon-payment-mastercard"></i>
            </span>
          </li>

          <li>
            <span class="payment-icon">
              <i class="icon-payment-american-express"></i>
            </span>
          </li>

          <li>
            <span class="payment-icon">
              <i class="icon-payment-discover"></i>
            </span>
          </li>

          <li>
            <span class="payment-icon">
              <i class="icon-payment-paypal"></i>
            </span>
          </li>

          <li>
            <span class="payment-icon">
              <i class="icon-payment-apple-pay"></i>
            </span>
          </li>
      </ul>

      <div data-content-region="ssl_site_seal--global"></div>
    </div>
  </div>

  <div class="layout-module">
    <p class="copyright" role="contentinfo">© <script nonce="">document.write(new Date().getFullYear())</script>2025 <a href="https://peptidestandard.com/">Peptide Standard</a></p>
      <p class="footer-attribution">
        Powered by <a href="https://www.bigcommerce.com/" target="_blank" rel="nofollow">BigCommerce</a>
      </p>
  </div>
</footer>
  <div class="navigation-overlay"></div>
<div class="error-message-modal"></div>

<div class="search-overlay">

  <!-- snippet location forms_search -->

  <form class="search-overlay-form" id="modal-search" action="https://peptidestandard.com/search.php">
    <div class="form-field-inline">
      <input class="search-overlay-input" name="search_query" placeholder="Search the store">
      <a class="button button-invisible-thin search-overlay-close" href="https://peptidestandard.com/store/tesamorelin/#modal-search">
        <i class="icon-close"><span class="sr-only">Close</span></i>
      </a>
    </div>
    <input class="button button-invisible search-overlay-submit" type="submit" value="Search">
  </form>

</div>


<div class="loading-overlay">
  <span class="page-spinner"></span>
</div>

  
<script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://peptidestandard.com/","name":"Home"}},{"@type":"ListItem","position":2,"item":{"@id":"https://peptidestandard.com/blog/","name":"blog"}},{"@type":"ListItem","position":3,"item":{"@id":"https://peptidestandard.com/store/tesamorelin/","name":"Tesamorelin"}}]}</script>

  <script nonce="">window.__webpack_public_path__ = "https://cdn11.bigcommerce.com/s-q1sponaupn/stencil/5bfdbf40-0203-013e-7707-7ab084116f26/e/a8ba4540-0218-013e-bf9c-661f783446da/dist/";</script>
  <script nonce="" src="./Tesamorelin - Peptide Standard_files/theme-bundle.main.js"></script>
  <script nonce="">
    window.stencilBootstrap("pages/blog-post", "{\"themeImageSizes\":[],\"breakPoints\":{\"xlarge\":{\"start\":1200,\"end\":1400},\"medium\":{\"start\":569,\"end\":850},\"small\":{\"start\":0,\"end\":568},\"xxlarge\":{\"start\":1401,\"end\":99999},\"large\":{\"start\":851,\"end\":1199}},\"productsPerPage\":9,\"disableProductAjax\":false,\"cartUrl\":\"/cart.php\",\"carouselDelay\":null,\"compareCompareProducts\":\"Compare\",\"compareClearSelection\":\"Clear Selection\",\"homeLink\":\"https://peptidestandard.com/\",\"continueShopping\":\"continue shopping\",\"urlsCart\":\"/cart.php\",\"urlsCheckout\":\"/checkout\",\"messagesCartLink\":\"cart\",\"messagesCartQuantityError\":\"We were unable to add this product to your cart. Please try again later. Contact us if you continue to have issues.\",\"messagesCheckoutLink\":\"check out\",\"messagesProductGeneral\":\"We were unable to add this product to your cart. Please try again later. Contact us if you continue to have issues.\",\"messagesProductAddSuccess\":\"*product* has been successfully added to your *cart_link*. Feel free to *continue_link* or *checkout_link*.\",\"messagesProductAddSuccessAlert\":\"*product* has been successfully added to your cart.\",\"productOutOfStock\":\"Unfortunately, we do not have *quantity* in stock.\",\"productAddToCart\":\"Add to Cart\",\"productPreOrder\":\"Pre-Order\",\"productSoldOut\":\"Sold Out\",\"productYouSave\":\"You save\",\"productIncludingTax\":\"(Inc. Tax)\",\"productExcludingTax\":\"(Exc. Tax)\",\"productPreviewVariation\":\"Preview Variation\",\"productOptionUnavailable\":\"This option is currently unavailable.\",\"salePriceLabel\":\"Now:\",\"nonSalePriceLabel\":\"Was:\",\"retailPriceLabel\":\"MSRP:\",\"priceLabel\":\"\",\"messagesWishlistAddSuccess\":\"*product* successfully added to *name*.\",\"messagesWishlistAddError\":\"*product* could not be added to wishlist.\",\"validationRequired\":\"This field is required.\",\"validationEmail\":\"Your E-mail address appears to be invalid.\",\"validationNumber\":\"You can enter only numbers in this field.\",\"validationNumMax\":\"Please enter a number less than undefined.\",\"validationNumMin\":\"Please enter a number greater than undefined.\",\"validationNumRange\":\"Please enter a number greater than undefined and less than undefined.\",\"validationMaxLength\":\"Maximum undefined characters allowed.\",\"validationMinLength\":\"Minimum undefined characters allowed.\",\"validationMaxChecked\":\"Maximum undefined options allowed.\",\"validationMinChecked\":\"Please select minimum undefined options.\",\"validationMaxSelected\":\"Maximum undefined selection allowed.\",\"validationMinSelected\":\"Minimum undefined selection allowed.\",\"validationNotEqual\":\"Fields do not match.\",\"validationDifferent\":\"Fields cannot be the same as each other.\",\"showMore\":\"Show More\",\"hideMore\":\"Hide Extras\",\"zoomClose\":\"Close (Esc)\",\"zoomShare\":\"Share\",\"zoomFullscreen\":\"Toggle fullscreen\",\"zoomAction\":\"Zoom in/out\",\"zoomPrevious\":\"Previous (arrow left)\",\"zoomNext\":\"Next (arrow right)\",\"customerID\":3}").load();
  </script>
  <script type="text/javascript" src="./Tesamorelin - Peptide Standard_files/csrf-protection-header-5eeddd5de78d98d146ef4fd71b2aedce4161903e.js"></script>
<script src="./Tesamorelin - Peptide Standard_files/collector.js" async=""></script><script src="./Tesamorelin - Peptide Standard_files/q1sponaupn.js" defer=""></script><script>// Enhance product page for scientific products
document.addEventListener('DOMContentLoaded', function() {
  // Only run on product pages
  if (!document.querySelector('.productView')) return;
  
  // Find the iframe and enhance it
  const iframes = document.querySelectorAll('.productView-description iframe');
  iframes.forEach(iframe => {
    const wrapper = document.createElement('div');
    wrapper.className = 'molecule-display';
    iframe.parentNode.insertBefore(wrapper, iframe);
    wrapper.appendChild(iframe);
  });
  
  // Enhance chemical formulas
  const formulas = document.querySelectorAll('.productView-info-value');
  formulas.forEach(formula => {
    if (formula.textContent.includes('Molecular Formula')) {
      formula.classList.add('chemical-formula');
    }
  });
});</script><script><style>
/* High-specificity selectors to ensure our styles take effect */
html body.page-type-product .productView-title,
html body.page-type-product h1.productView-title {
  font-weight: 800 !important;
  text-transform: uppercase !important;
  border-bottom: 2px solid #3fe2ae !important;
  display: inline-block !important;
  padding-bottom: 5px !important;
  color: #ffffff !important;
}

html body.page-type-product .productView,
html body.page-type-product div.productView {
  background-color: rgba(18, 18, 18, 0.8) !important;
  color: #ffffff !important;
  padding: 20px !important;
  border-radius: 10px !important;
  margin-top: 20px !important;
}

html body.page-type-product .productView-details,
html body.page-type-product div.productView-details {
  background: rgba(30, 30, 30, 0.8) !important;
  border-radius: 10px !important;
  padding: 20px !important;
  margin-bottom: 20px !important;
  border: 1px solid rgba(255, 255, 255, 0.1) !important;
  box-shadow: 0 5px 15px rgba(0, 0, 0, 0.2) !important;
}

html body.page-type-product .productView-info-name,
html body.page-type-product span.productView-info-name {
  color: rgba(255, 255, 255, 0.7) !important;
  font-weight: 600 !important;
}

html body.page-type-product .productView-info-value,
html body.page-type-product span.productView-info-value {
  color: #ffffff !important;
  font-weight: 500 !important;
}

html body.page-type-product .productView-price .price,
html body.page-type-product span.price {
  color: #3fe2ae !important;
  font-weight: 700 !important;
}

html body.page-type-product .button--primary,
html body.page-type-product button.button--primary {
  background: linear-gradient(45deg, #ff6448 0%, #3fe2ae 100%) !important;
  border: none !important;
  border-radius: 5px !important;
  color: white !important;
  font-weight: 600 !important;
  transition: all 0.3s ease !important;
}

html body.page-type-product .productView-description,
html body.page-type-product div.productView-description {
  background: rgba(30, 30, 30, 0.8) !important;
  border-radius: 10px !important;
  padding: 30px !important;
  margin-top: 30px !important;
  border: 1px solid rgba(255, 255, 255, 0.1) !important;
  box-shadow: 0 5px 15px rgba(0, 0, 0, 0.2) !important;
  color: #ffffff !important;
}

html body.page-type-product .productView-description iframe,
html body.page-type-product div.productView-description iframe {
  border-radius: 8px !important;
  margin: 20px auto !important;
  display: block !important;
  box-shadow: 0 5px 15px rgba(0, 0, 0, 0.3) !important;
}

html body.page-type-product .form-input, 
html body.page-type-product .form-select,
html body.page-type-product input.form-input,
html body.page-type-product select.form-select {
  background-color: rgba(255, 255, 255, 0.1) !important;
  border: 1px solid rgba(255, 255, 255, 0.1) !important;
  border-radius: 5px !important;
  color: white !important;
}

/* Target the entire page background */
html body.page-type-product,
html body.page-type-product div.body,
html body.page-type-product div.page,
html body.page-type-product div.page-content {
  background-color: #121212 !important;
  color: #ffffff !important;
}
</style>


// Enhance molecular visualization
document.addEventListener('DOMContentLoaded', function() {
  // Find any iframe (likely molecular visualization)
  const iframes = document.querySelectorAll('.productView-description iframe');
  
  if (iframes.length > 0) {
    iframes.forEach(iframe => {
      // Create wrapper for the iframe
      const wrapper = document.createElement('div');
      wrapper.className = 'molecule-wrapper';
      wrapper.style.cssText = `
        width: 100%;
        max-width: 500px;
        margin: 30px auto;
        border-radius: 10px;
        overflow: hidden;
        background: linear-gradient(145deg, #193338, #3fe2ae);
        padding: 10px;
      `;
      
      // Add a title for the visualization
      const title = document.createElement('h3');
      title.textContent = 'Molecular Structure';
      title.style.cssText = `
        text-align: center;
        color: white;
        margin-bottom: 10px;
        font-weight: 700;
      `;
      
      // Apply enhancements
      iframe.parentNode.insertBefore(wrapper, iframe);
      wrapper.appendChild(title);
      wrapper.appendChild(iframe);
      
      iframe.style.width = '100%';
      iframe.style.height = '300px';
      iframe.style.border = 'none';
      iframe.style.borderRadius = '8px';
      iframe.style.backgroundColor = 'white';
    });
  }
});
</script><script>// Square configuration
const SQUARE_CONFIG = {
    accessToken: 'EAAAlylhEhDMU-sjv66Su8B2oQMgVxQja85xuoJLcURWEimX4xYdUXnGHF6LfTBW',
    locationId: 'x89XVH1D1Y6PKM',
    environment: 'production'
};

// Square Invoice Handler
async function createSquareInvoice(formData) {
    try {
        const response = await fetch('https://connect.squareup.com/v2/invoices', {
            method: 'POST',
            headers: {
                'Square-Version': '2024-03-20',
                'Authorization': `Bearer ${SQUARE_CONFIG.accessToken}`,
                'Content-Type': 'application/json'
            },
            body: JSON.stringify({
                invoice: {
                    location_id: SQUARE_CONFIG.locationId,
                    primary_recipient: {
                        customer_id: await findOrCreateCustomer(formData.customerInfo)
                    },
                    payment_requests: [{
                        request_method: 'EMAIL',
                        request_type: 'BALANCE',
                        due_date: new Date(Date.now() + 30 * 24 * 60 * 60 * 1000).toISOString().split('T')[0]
                    }],
                    delivery_method: 'EMAIL',
                    line_items: formData.lineItems.map(item => ({
                        quantity: item.quantity.toString(),
                        name: item.product,
                        base_price_money: {
                            amount: Math.round(parseFloat(item.price) * 100),
                            currency: 'USD'
                        }
                    }))
                }
            })
        });

        if (!response.ok) {
            throw new Error('Failed to create invoice');
        }

        const result = await response.json();
        alert('Invoice created successfully!');
        return result;
    } catch (error) {
        console.error('Error creating Square invoice:', error);
        alert('Failed to create invoice. Please try again.');
        throw error;
    }
}

// Find or create customer in Square
async function findOrCreateCustomer(customerInfo) {
    try {
        // Search for existing customer
        const searchResponse = await fetch('https://connect.squareup.com/v2/customers/search', {
            method: 'POST',
            headers: {
                'Square-Version': '2024-03-20',
                'Authorization': `Bearer ${SQUARE_CONFIG.accessToken}`,
                'Content-Type': 'application/json'
            },
            body: JSON.stringify({
                query: {
                    filter: {
                        email_address: {
                            exact: customerInfo.email
                        }
                    }
                }
            })
        });

        const searchResult = await searchResponse.json();
        
        if (searchResult.customers?.length > 0) {
            return searchResult.customers[0].id;
        }

        // Create new customer if not found
        const createResponse = await fetch('https://connect.squareup.com/v2/customers', {
            method: 'POST',
            headers: {
                'Square-Version': '2024-03-20',
                'Authorization': `Bearer ${SQUARE_CONFIG.accessToken}`,
                'Content-Type': 'application/json'
            },
            body: JSON.stringify({
                idempotency_key: Date.now().toString(),
                given_name: customerInfo.name,
                email_address: customerInfo.email,
                phone_number: customerInfo.phone,
                address: {
                    address_line_1: customerInfo.address,
                    locality: customerInfo.city,
                    administrative_district_level_1: customerInfo.state,
                    postal_code: customerInfo.zip,
                    country: 'US'
                }
            })
        });

        const createResult = await createResponse.json();
        return createResult.customer.id;
    } catch (error) {
        console.error('Error finding/creating customer:', error);
        throw error;
    }
}

// Initialize when DOM is loaded
document.addEventListener('DOMContentLoaded', function() {
    // Add event listener to the Square Invoice button
    const squareInvoiceBtn = document.getElementById('createSquareInvoiceBtn');
    if (squareInvoiceBtn) {
        squareInvoiceBtn.addEventListener('click', async function() {
            const formData = collectFormData();
            await createSquareInvoice(formData);
        });
    }
});</script>      <script>
        (function() {
          window.shogunVariables = {};
          window.shogunVariables.orderId = '';
        })();
      </script>
<script>
(function(){if(!window.chatbase||window.chatbase("getState")!=="initialized"){window.chatbase=(...arguments)=>{if(!window.chatbase.q){window.chatbase.q=[]}window.chatbase.q.push(arguments)};window.chatbase=new Proxy(window.chatbase,{get(target,prop){if(prop==="q"){return target.q}return(...args)=>target(prop,...args)}})}const onLoad=function(){const script=document.createElement("script");script.src="https://www.chatbase.co/embed.min.js";script.id="rcNL6wxGDLSXXSo1wljpQ";script.domain="www.chatbase.co";document.body.appendChild(script)};if(document.readyState==="complete"){onLoad()}else{window.addEventListener("load",onLoad)}})();
</script>

  <!-- snippet location footer -->
  

<script src="./Tesamorelin - Peptide Standard_files/embed.min.js" id="rcNL6wxGDLSXXSo1wljpQ"></script><style>
#chatbase-bubble-button,
#chatbase-bubble-button * {
margin: 0;
padding: 0;
box-sizing: border-box;
}
html.__cb_widget_active,
html.__cb_widget_active body {
position: fixed !important;
top: 0;
left: 0;
overscroll-behavior: none;
width: 0 !important;
height: 0 !important;
margin: 0 !important;
overflow: hidden !important;
overflow-y: hidden !important;
overflow-x: hidden !important;
transform: none !important;
}

#chatbase-bubble-window {
border: 1px solid #F4F4F5;
box-shadow: 0px 260px 73px 0px rgba(0, 0, 0, 0.00), 0px 166px 67px 0px rgba(0, 0, 0, 0.01), 0px 94px 56px 0px rgba(0, 0, 0, 0.02), 0px 42px 42px 0px rgba(0, 0, 0, 0.03), 0px 10px 23px 0px rgba(0, 0, 0, 0.04);
backdrop-filter: blur(4px);
-webkit-backdrop-filter: blur(4px);
}

</style><div id="chatbase-message-bubbles" style="position: fixed; bottom: 85px; border-radius: 10px; font-family: sans-serif; font-size: 16px; z-index: 2147483644; cursor: pointer; flex-direction: column; gap: 50px; max-width: 70vw; display: block; right: 1rem; left: unset;"><div style="position: absolute; top: -7px; right: -7px; font-weight: bold; display: none; justify-content: center; align-items: center; z-index: 2147483643; width: 22px; height: 22px; border-radius: 50%; text-align: center; font-size: 12px; cursor: pointer; background-color: rgb(51, 51, 51); color: white; box-shadow: rgba(150, 150, 150, 0.15) 0px 6px 24px 0px, rgba(150, 150, 150, 0.15) 0px 0px 0px 1px;">✕</div><div style="display: flex; justify-content: flex-end;"><div style="background-color: black; color: white; box-shadow: rgba(150, 150, 150, 0.2) 0px 10px 30px 0px, rgba(150, 150, 150, 0.2) 0px 0px 0px 1px; border-radius: 10px; padding: 20px; margin: 8px; font-size: 14px; opacity: 1; transform: scale(1); transition: opacity 0.5s, transform 0.5s;">Hey there! You need assistance with anything?</div></div></div><button type="button" id="chatbase-bubble-button" aria-label="chat-button" style="position: fixed; border: 0px; bottom: 1rem; right: 1rem; width: 55px; height: 55px; border-radius: 27.5px; background-color: rgb(243, 255, 168); box-shadow: rgba(0, 0, 0, 0.2) 0px 4px 8px 0px; cursor: pointer; z-index: 2147483645; transition: 0.2s ease-in-out; left: unset;"><div style="display: flex; align-items: center; justify-content: center; width: 100%; height: 100%; z-index: 2147483646;"><img src="./Tesamorelin - Peptide Standard_files/bV4iIfaGa67MbMybykThp.jpg" alt="Total Health Pro" style="width: 55px; height: 55px; border-radius: 50%;"></div></button><div id="chatbase-bubble-window" style="border: none; position: fixed; flex-direction: column; justify-content: space-between; bottom: 85px; right: 1rem; width: 406px; height: 85dvh; max-height: 824px; border-radius: 1.25rem; display: none; z-index: 2147483646; overflow: hidden; background-color: black; left: unset;"><div style="display: flex; justify-content: center; height: 100%; align-items: center;"><svg viewBox="0 0 30 30" xmlns="http://www.w3.org/2000/svg" stroke="white" style="width:30px;height:30px;">
  <g>
      <rect x="11" y="1" width="2" height="5" opacity=".14"></rect>
      <rect x="11" y="1" width="1" height="5" transform="rotate(30 12 12)" opacity=".29"></rect>
      <rect x="11" y="1" width="1" height="5" transform="rotate(60 12 12)" opacity=".43"></rect>
      <rect x="11" y="1" width="1" height="5" transform="rotate(90 12 12)" opacity=".57"></rect>
      <rect x="11" y="1" width="1" height="5" transform="rotate(120 12 12)" opacity=".71"></rect>
      <rect x="11" y="1" width="1" height="5" transform="rotate(150 12 12)" opacity=".86"></rect>
      <rect x="11" y="1" width="1" height="5" transform="rotate(180 12 12)"></rect>
      <animatetransform attributeName="transform" type="rotate" calcMode="discrete" dur="0.75s" values="0 12 12;30 12 12;60 12 12;90 12 12;120 12 12;150 12 12;180 12 12;210 12 12;240 12 12;270 12 12;300 12 12;330 12 12;360 12 12" repeatCount="indefinite"></animatetransform>
  </g>
</svg></div><iframe title="Total Health Pro" style="height: 100%; width: 100%; border: none; display: none;" src="./Tesamorelin - Peptide Standard_files/saved_resource(1).html"></iframe></div></body></html>